


Inflammation in asthma is heterogeneous and dynamic¹⁻⁴

Patients can have concurrent overlapping pathways, and their dominant pathway can change over time¹⁻⁴



In a study investigating phenotype stability by sputum analysis, ~50% of patients with asthma changed their biomarker profile after 1 year of follow up^{3,a}

The number of lines is a relative representation of the number of patients. Eos high: $\geq 2\%$; Neu high: $\geq 40\%$ in induced sputum

^aPhenotype change (based on biomarkers) in full cohort (included patients with mild/moderate and severe asthma; n= 52)

Eos = Eosinophils; Neu = Neutrophils

1. Busse WW. *Allergol Int.* 2019;68:158-166. 2. Canonica GW. Oral presentation at WAC 2019 (Abstract OC35). 3. Kupczyk M, et al. *Allergy.* 2014;69:1198-1204. 4. Tran TN et al. *Ann Allergy Asthma Immunol.* 2016;116:37-42.